Akebia Therapeutics Inc (AKBA)
1.155
+0.02
(+1.32%)
USD |
NASDAQ |
May 17, 16:00
1.155
0.00 (0.00%)
After-Hours: 20:00
Akebia Therapeutics Research and Development Expense (Annual): 63.08M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 63.08M |
| December 31, 2022 | 129.99M |
| December 31, 2021 | 147.85M |
| December 31, 2020 | 218.48M |
| December 31, 2019 | 322.97M |
| December 31, 2018 | 291.01M |
| Date | Value |
|---|---|
| December 31, 2017 | 230.89M |
| December 31, 2016 | 115.78M |
| December 31, 2015 | 43.02M |
| December 31, 2014 | 23.26M |
| December 31, 2013 | 8.902M |
| December 31, 2012 | 5.632M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
63.08M
Minimum
2023
322.97M
Maximum
2019
176.47M
Average
147.85M
Median
2021
Research and Development Expense (Annual) Benchmarks
| Ocugen Inc | 39.57M |
| Aquestive Therapeutics Inc | 13.10M |
| Amicus Therapeutics Inc | 152.38M |
| Insmed Inc | 571.01M |
| InfuSystems Holdings Inc | -- |